Rockwell Medical (RMTI) Scheduled to Post Quarterly Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) will be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Rockwell Medical has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $22.68 million during the quarter, compared to the consensus estimate of $21.18 million. Rockwell Medical had a negative net margin of 9.72% and a negative return on equity of 28.29%. During the same period in the prior year, the firm earned ($0.10) earnings per share. On average, analysts expect Rockwell Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Rockwell Medical Stock Performance

Rockwell Medical stock opened at $1.77 on Wednesday. Rockwell Medical has a fifty-two week low of $1.16 and a fifty-two week high of $3.16. The stock’s 50 day simple moving average is $1.85 and its two-hundred day simple moving average is $1.63. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.38 and a current ratio of 1.79. The stock has a market cap of $53.67 million, a price-to-earnings ratio of -4.92 and a beta of 1.43.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. StockNews.com raised Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, June 19th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Rockwell Medical in a research report on Thursday, May 16th.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.